• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Autonomix Medical Inc.

    4/2/26 5:00:32 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care
    Get the next $AMIX alert in real time by email
    S-8 1 amix20260326_s8.htm FORM S-8 amix20260326_s8.htm

     

    As filed with the Securities and Exchange Commission on April 2, 2026

    Registration No. 333- 

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Autonomix Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    47-1607810

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer Identification Number)

         

    21 Waterway Avenue, Suite 300

    The Woodlands, Texas

     

    77380

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Autonomix Medical, Inc. 2023 Stock Plan

    (Full title of the plans)

     

    Brad Hauser

    Chief Executive Officer

    21 Waterway Avenue, Suite 300

    The Woodlands, Texas 77380

    (713) 588-6150

    (Name, address, including zip code, and telephone number,

    including area code, of agent for service)

     

    Copies to:

     

    Cavas S. Pavri, Esq.

    ArentFox Schiff LLP

    1717 K Street, NW

    Washington, DC 20006

    (202) 724-6847

    Facsimile: (202) 778-6460

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934. (Check one):

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

       

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    PART I

     

    INFORMATION REQUIRED PURSUANT

    TO GENERAL INSTRUCTION E TO FORM S-8

     

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of Autonomix Medical, Inc. (the “Registrant”) on Form S-8 relating to the same employee benefit plan is effective. This Registration Statement registers an additional 2,595,319 shares of common stock of the Registrant to be issued pursuant to the Registrant’s 2023 Stock Plan, as amended (the “Equity Plan”), which includes (i) 1,900,000 shares of common stock approved at the Registrant’s 2025 annual meeting of stockholders, and (ii) 695,319 shares of common stock pursuant to the “evergreen” provision of the Equity Plan. The contents of the previous Registration Statement on Form S-8 filed by us with the Securities and Exchange Commission for the Equity Plan on May 31, 2024 (file no. 333-279894), including any amendments thereto, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Securities and Exchange Commission:

     

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended March 31, 2025, as amended (filed on May 29, 2025);

     

     

    (b)

    The Registrant’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2025 (filed on August 13, 2025); September 30, 2025 (filed on November 12, 2025); and December 31, 2025 (filed on February 11, 2026);

     

     

    (c)

    The Registrant’s Current Reports of Form 8-K filed on July 22, 2025; August 26, 2025; August 27, 2025; November 3, 2025; November 19, 2025; and January 16, 2026;

     

     

    (d)

    The Registrant’s Definitive Proxy Statement on Schedule 14A filed on September 12, 2025; and

     

    (e) The description of the Registrant’s common stock, par value $0.001 per share contained in its Registration Statement on Form 8-A, dated and filed with the SEC on January 26, 2024, and any amendment, exhibit to our Annual Report on Form 10-K or report filed with the SEC for the purpose of updating the description.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, subsequent to the date hereof and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall also be deemed to be incorporated by reference herein and to be a part hereof from the dates of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits. 

     

    Exhibit

    Number

     

    Description

    4.1

     

    Amended and Restated Certificate of Incorporation of Autonomix Medical, Inc. (incorporated by reference from exhibit 2.1 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

    4.2

     

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Autonomix Medical, Inc., filed with the Secretary of State of the State of Delaware (incorporated by reference from exhibit 3.1 of the Form 8-K filed October 28, 2024)

    4.3

     

    Amended and Restated Bylaws of Autonomix Medical, Inc. (incorporated by reference from exhibit 2.2 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

    4.4*

     

    Autonomix Medical, Inc. 2023 Stock Plan, as amended and restated and forms of award agreements

    5.1*

     

    Opinion of ArentFox Schiff, LLP

    23.1*

     

    Consent of Forvis Mazars, LLP

    23.2*

     

    Consent of ArentFox Schiff LLP (included in exhibit 5.1)

    24.1*

     

    Power of Attorney (included on the signature page)

    107*

     

    Filing fee table

    * Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of The Woodlands, Texas, on April 2, 2026.

     

     

    Autonomix Medical, Inc.

     

    (Registrant)

     
         
     

    By:

    /s/ Brad Hauser

     
       

    Brad Hauser

     
       

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brad Hauser or Trent Smith as attorney-in-fact and agent, with full power of substitution and re-substitution, to sign on his or her behalf, individually and in any and all capacities, including the capacities stated below, any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting to said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:

     

    SIGNATURE

     

    TITLE

     

    DATE

             

    /s/ Brad Hauser

     

    Chief Executive Officer and Director

       

    Brad Hauser

     

    (Principal Executive Officer)

     

     April 2, 2026

             

    /s/ Trent Smith

     

    Chief Financial Officer

       

    Trent Smith

     

    (Principal Financial Officer and Principal Accounting Officer)

     

     April 2, 2026

             

    /s/ Walter V. Klemp

           

    Walter V. Klemp

     

    Director

     

     April 2, 2026

             

    /s/ Lori Bisson

           

    Lori Bisson

     

    Director

     

     April 2, 2026

             

    /s/ Jonathan P. Foster

           

    Jonathan P. Foster

     

    Director

     

     April 2, 2026

             

    /s/ David Robins

           

    David Robins

     

    Director

     

     April 2, 2026

             

    /s/ Christopher Capelli

           

    Christopher Capelli

     

    Director

     

     April 2, 2026

     
    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMIX
    SEC Filings

    View All

    SEC Form S-8 filed by Autonomix Medical Inc.

    S-8 - Autonomix Medical, Inc. (0001617867) (Filer)

    4/2/26 5:00:32 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Autonomix Medical Inc.

    10-Q - Autonomix Medical, Inc. (0001617867) (Filer)

    2/11/26 5:00:59 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Autonomix Medical, Inc. (0001617867) (Filer)

    1/16/26 7:30:35 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autonomix Medical to Present at LSI USA '26

    THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer of Autonomix will present at LSI USA '26 on Tuesday, March 17, 2026 at 9:15 AM PT. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. The in-person presentation will be accessible to those registered to attend the event. For more information, please visit the co

    3/11/26 8:40:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical Selected for Best Innovation Competition at CRT 2026

    THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, "Illuminating The Nervous System With Transvascular Precision-guided Technology," has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026. The presentation will be delivered by Chief Executive Officer, Brad Hauser, on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET in the International Ballroom – West. The CRT Best Innovation Competition highlights transformative tec

    3/5/26 8:45:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

    THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, "Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes," will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 - 2:24p ET for Hypertension Therapies

    3/4/26 8:40:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Hauser Bradley

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:19:59 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Capelli Christopher

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:16:29 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Klemp Walter V

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:13:57 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Leadership Updates

    Live Leadership Updates

    View All

    Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

    Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th

    12/19/24 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

    Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

    6/17/24 4:05:00 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Appoints Jennifer Cook as Chief Business Officer

    Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

    3/19/24 8:45:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    10/7/24 8:30:24 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care